| ■ 영문 제목 : Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR70733-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2022년 12월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 162 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의약품 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사는 세계의 만성 폐색성 폐질환 치료제 시장 규모가 2022년부터 2027년까지 연평균 6.09% 성장하여, 6654.49백만 달러에 달할 것으로 예측하고 있습니다. 본 연구 보고서에서는세계의 만성 폐색성 폐질환 치료제 시장에 대해 다방면으로 조사 및 분석하여, 개요, 시장 현황, 시장 규모, 과거 시장 규모, Five Force 분석, 제품별 (병용 요법, 단독 요법) 분석, 판매 채널별 (병원 약국, 소매 약국, 온라인 약국) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아 태평양, 미국, 영국, 캐나다, 독일, 일본, 기타 지역) 분석, 추진 요인/과제/동향, 기업 현황, 기업 분석 등의 항목을 게재하고 있습니다. 또한 본 자료는 AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd. 등의 기업 정보가 포함되어 있습니다. ・개요 ・시장 현황 ・시장 규모 ・과거 시장 규모 ・Five Force 분석 ・세계의 만성 폐색성 폐질환 치료제 시장 규모 : 제품별 - 병용 요법 만성 폐색성 폐질환 치료제의 시장 규모 - 단독 요법 만성 폐색성 폐질환 치료제의 시장 규모 ・세계의 만성 폐색성 폐질환 치료제 시장 규모 : 판매 채널별 - 병원 약국 채널의 시장 규모 - 소매 약국 채널의 시장 규모 - 온라인 약국 채널의 시장 규모 ・고객 현황 ・지역별 현황 - 북미의 만성 폐색성 폐질환 치료제 시장 규모 - 유럽의 만성 폐색성 폐질환 치료제 시장 규모 - 아시아 태평양의 만성 폐색성 폐질환 치료제 시장 규모 - 미국의 만성 폐색성 폐질환 치료제 시장 규모 - 영국의 만성 폐색성 폐질환 치료제 시장 규모 - 캐나다의 만성 폐색성 폐질환 치료제 시장 규모 - 독일의 만성 폐색성 폐질환 치료제 시장 규모 - 일본의 만성 폐색성 폐질환 치료제 시장 규모 - 기타 지역의 만성 폐색성 폐질환 치료제 시장 규모 ・추진 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
글로벌 만성 폐쇄성 폐질환(COPD) 약물 시장에 대한 Technavio의 보고서는 2022-2027년 동안 시장 규모가 6654.49백만 달러 성장하고, 연평균 성장률(CAGR)이 6.09%에 이를 것으로 예측하고 있습니다. 이 보고서는 COPD 약물 시장의 현재 상황, 최신 동향 및 성장 동력, 도전 과제를 포괄적으로 분석하고 있으며, 약 25개의 주요 공급업체에 대한 분석도 포함하고 있습니다.
COPD 약물 시장의 주요 성장 요인은 COPD의 증가하는 유병률, 강력한 파이프라인과 신약 승인, 복합제에 대한 증가하는 수요입니다. 시장은 제품, 유통 채널 및 지리적 경관에 따라 세분화되어 있습니다. 제품 측면에서는 복합 요법과 단일 요법으로 나뉘며, 유통 채널은 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다. 지리적 측면에서는 북미, 유럽, 아시아, 나머지 세계(ROW)로 나뉘어 있습니다.
이 연구는 향후 몇 년간 만성 폐쇄성 폐질환 약물 시장의 성장 원인 중 하나로 치료적 접근법에 대한 연구 확대를 지목하고 있습니다. 또한, 약물 전달 장치의 발전과 금연을 위한 전자 담배 및 기타 제품 사용 증가가 시장 수요를 크게 증가시킬 것으로 예상됩니다.
Technavio의 보고서는 COPD 약물 시장의 크기, 예측 및 산업 분석을 상세히 다루고 있으며, 시장 위치 개선을 위한 강력한 공급업체 분석도 제공합니다. 분석에는 AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd. 등이 포함됩니다.
이 보고서는 향후 시장 성장에 영향을 미칠 주요 동향과 도전 과제에 대한 정보도 포함하고 있어 기업들이 전략을 수립하고 성장 기회를 활용하는 데 도움을 줍니다. 연구는 주요 산업 참여자들의 정보를 포함한 1차 및 2차 정보를 객관적으로 조합하여 수행되었습니다. 보고서는 포괄적인 시장 및 공급업체 환경과 함께 주요 공급업체 분석을 포함합니다. Technavio의 시장 조사 보고서는 경쟁력 있는 시장 환경과 심층 공급업체 선택 방법론을 제공하며, 질적 및 양적 연구를 통해 정확한 시장 성장을 예측합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 o 표 34: 병용 요법 – 시장 규모 및 전망 차트(2022-2027년, 백만 달러) o 표 51: 소매 약국 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) • 8 고객 현황 • 9 지역별 현황 o 표 73: 아시아 시장 규모 및 전망 차트 2022-2027 (백만 달러) o 표 77: 기타 지역(ROW) 차트 – 2022-2027년 시장 규모 및 전망 (백만 달러) o 표 97: 일본 시장 – 2022-2027년 시장 규모 및 전망 (백만 달러) 차트 o 표 105: 주요 위험이 사업에 미치는 영향 • 12 공급업체 분석 o 12.1 분석 대상 공급업체 o 12.2 공급업체의 시장 포지셔닝 o 표 148: 시오노기 주식회사 – 개요 첨부자료 168: 제외 항목 체크리스트 13.3 미국 달러 환율 첨부자료 169: 미국 달러 환율 13.4 연구 방법론 첨부자료 170: 연구 방법론 첨부자료 171: 시장 규모 산정에 사용된 검증 기법 첨부자료 172: 정보 출처 13.5 약어 목록 첨부자료 173: 약어 목록 첨부자료: 첨부자료 1: 요약 – 시장 개요 차트 첨부자료 2: 요약 – 시장 개요 데이터 표 첨부자료 3: 요약 – 글로벌 시장 특성 차트 첨부자료 4: 요약 – 지역별 시장 현황 차트 첨부자료 5: 요약 – 제품별 시장 세분화 차트 첨부자료 6: 요약 – 시장 세분화 차트 유통 채널별 표 표 26: 신규 진입자의 위협 – 2022년 및 2027년 주요 요인의 영향 표 52: 소매 약국 데이터 표 – 시장 규모 및 전망 2022-2027 (백만 달러) 첨부자료 143: 문디파마 인터내셔널 주식회사 – 주요 제품 및 서비스 첨부자료 157: 테바 제약(Teva Pharmaceutical Industries Ltd.) – 주요 뉴스 첨부자료 172: 정보 출처 첨부자료 173: 약어 목록 • 1 Executive Summaryo 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape o Exhibit 05: Executive Summary - Chart on Market Segmentation by Product o Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global chronic obstructive pulmonary disease drugs market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million) o 4.2 Product Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million) o 4.3 Distribution channel Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Product o 6.1 Market segments o Exhibit 30: Chart on Product - Market share 2022-2027 (%) o Exhibit 31: Data Table on Product - Market share 2022-2027 (%) o 6.2 Comparison by Product o Exhibit 32: Chart on Comparison by Product o Exhibit 33: Data Table on Comparison by Product o 6.3 Combination therapy - Market size and forecast 2022-2027 o Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%) o 6.4 Monotherapy - Market size and forecast 2022-2027 o Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Product o Exhibit 42: Market opportunity by Product ($ million) • 7 Market Segmentation by Distribution Channel o 7.1 Market segments o Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%) o Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%) o 7.2 Comparison by Distribution Channel o Exhibit 45: Chart on Comparison by Distribution Channel o Exhibit 46: Data Table on Comparison by Distribution Channel o 7.3 Hospital pharmacies - Market size and forecast 2022-2027 o Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%) o 7.4 Retail pharmacies - Market size and forecast 2022-2027 o Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%) o 7.5 Online pharmacies - Market size and forecast 2022-2027 o Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%) o 7.6 Market opportunity by Distribution Channel o Exhibit 59: Market opportunity by Distribution Channel ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%) o Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 63: Chart on Geographic comparison o Exhibit 64: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 UK - Market size and forecast 2022-2027 o Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.9 Canada - Market size and forecast 2022-2027 o Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.10 Germany - Market size and forecast 2022-2027 o Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.11 Japan - Market size and forecast 2022-2027 o Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million) o Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million) o Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%) o Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity By Geographical Landscape o Exhibit 101: Market opportunity By Geographical Landscape ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 102: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 103: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 104: Overview on factors of disruption o 11.4 Industry risks o Exhibit 105: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 106: Vendors covered o 12.2 Market positioning of vendors o Exhibit 107: Matrix on vendor position and classification o 12.3 AstraZeneca Plc o Exhibit 108: AstraZeneca Plc - Overview o Exhibit 109: AstraZeneca Plc - Product / Service o Exhibit 110: AstraZeneca Plc - Key news o Exhibit 111: AstraZeneca Plc - Key offerings o 12.4 Boehringer Ingelheim International GmbH o Exhibit 112: Boehringer Ingelheim International GmbH - Overview o Exhibit 113: Boehringer Ingelheim International GmbH - Business segments o Exhibit 114: Boehringer Ingelheim International GmbH - Key news o Exhibit 115: Boehringer Ingelheim International GmbH - Key offerings o Exhibit 116: Boehringer Ingelheim International GmbH - Segment focus o 12.5 Cadila Pharmaceuticals Ltd. o Exhibit 117: Cadila Pharmaceuticals Ltd. - Overview o Exhibit 118: Cadila Pharmaceuticals Ltd. - Product / Service o Exhibit 119: Cadila Pharmaceuticals Ltd. - Key offerings o 12.6 Cipla Ltd. o Exhibit 120: Cipla Ltd. - Overview o Exhibit 121: Cipla Ltd. - Business segments o Exhibit 122: Cipla Ltd. - Key news o Exhibit 123: Cipla Ltd. - Key offerings o Exhibit 124: Cipla Ltd. - Segment focus o 12.7 Exela Pharma Sciences LLC o Exhibit 125: Exela Pharma Sciences LLC - Overview o Exhibit 126: Exela Pharma Sciences LLC - Product / Service o Exhibit 127: Exela Pharma Sciences LLC - Key offerings o 12.8 GlaxoSmithKline Plc o Exhibit 128: GlaxoSmithKline Plc - Overview o Exhibit 129: GlaxoSmithKline Plc - Business segments o Exhibit 130: GlaxoSmithKline Plc - Key offerings o Exhibit 131: GlaxoSmithKline Plc - Segment focus o 12.9 Lupin Ltd. o Exhibit 132: Lupin Ltd. - Overview o Exhibit 133: Lupin Ltd. - Product / Service o Exhibit 134: Lupin Ltd. - Key news o Exhibit 135: Lupin Ltd. - Key offerings o 12.10 Merck and Co. Inc. o Exhibit 136: Merck and Co. Inc. - Overview o Exhibit 137: Merck and Co. Inc. - Business segments o Exhibit 138: Merck and Co. Inc. - Key news o Exhibit 139: Merck and Co. Inc. - Key offerings o Exhibit 140: Merck and Co. Inc. - Segment focus o 12.11 Mundipharma International Ltd. o Exhibit 141: Mundipharma International Ltd. - Overview o Exhibit 142: Mundipharma International Ltd. - Product / Service o Exhibit 143: Mundipharma International Ltd. - Key offerings o 12.12 Novartis AG o Exhibit 144: Novartis AG - Overview o Exhibit 145: Novartis AG - Business segments o Exhibit 146: Novartis AG - Key offerings o Exhibit 147: Novartis AG - Segment focus o 12.13 Shionogi and Co. Ltd. o Exhibit 148: Shionogi and Co. Ltd. - Overview o Exhibit 149: Shionogi and Co. Ltd. - Product / Service o Exhibit 150: Shionogi and Co. Ltd. - Key offerings o 12.14 Sumitomo Pharma Co. Ltd. o Exhibit 151: Sumitomo Pharma Co. Ltd. - Overview o Exhibit 152: Sumitomo Pharma Co. Ltd. - Business segments o Exhibit 153: Sumitomo Pharma Co. Ltd. - Key offerings o Exhibit 154: Sumitomo Pharma Co. Ltd. - Segment focus o 12.15 Teva Pharmaceutical Industries Ltd. o Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview o Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments o Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news o Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings o Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus o 12.16 Theravance Biopharma Inc. o Exhibit 160: Theravance Biopharma Inc. - Overview o Exhibit 161: Theravance Biopharma Inc. - Product / Service o Exhibit 162: Theravance Biopharma Inc. - Key offerings o 12.17 Viatris Inc. o Exhibit 163: Viatris Inc. - Overview o Exhibit 164: Viatris Inc. - Business segments o Exhibit 165: Viatris Inc. - Key offerings o Exhibit 166: Viatris Inc. - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 167: Inclusions checklist o Exhibit 168: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 169: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 170: Research methodology o Exhibit 171: Validation techniques employed for market sizing o Exhibit 172: Information sources o 13.5 List of abbreviations o Exhibit 173: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market By Geographical Landscape Exhibits5: Executive Summary - Chart on Market Segmentation by Product Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Product Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Product - Market share 2022-2027 (%) Exhibits31: Data Table on Product - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Product Exhibits33: Data Table on Comparison by Product Exhibits34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Product ($ million) Exhibits43: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibits44: Data Table on Distribution Channel - Market share 2022-2027 (%) Exhibits45: Chart on Comparison by Distribution Channel Exhibits46: Data Table on Comparison by Distribution Channel Exhibits47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%) Exhibits50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%) Exhibits51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%) Exhibits54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%) Exhibits55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%) Exhibits58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%) Exhibits59: Market opportunity by Distribution Channel ($ million) Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%) Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%) Exhibits63: Chart on Geographic comparison Exhibits64: Data Table on Geographic comparison Exhibits65: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits66: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits67: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits68: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits69: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits70: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits71: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits72: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits73: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits74: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits75: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits76: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits81: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits82: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits83: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits84: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits85: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits86: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits87: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits88: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits89: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits90: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits91: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits92: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits93: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits94: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits95: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits96: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits97: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibits98: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibits99: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibits100: Data Table on Japan - Year-over-year growth 2022-2027 (%) Exhibits101: Market opportunity By Geographical Landscape ($ million) Exhibits102: Impact of drivers and challenges in 2022 and 2027 Exhibits103: Overview on Criticality of inputs and Factors of differentiation Exhibits104: Overview on factors of disruption Exhibits105: Impact of key risks on business Exhibits106: Vendors covered Exhibits107: Matrix on vendor position and classification Exhibits108: AstraZeneca Plc - Overview Exhibits109: AstraZeneca Plc - Product / Service Exhibits110: AstraZeneca Plc - Key news Exhibits111: AstraZeneca Plc - Key offerings Exhibits112: Boehringer Ingelheim International GmbH - Overview Exhibits113: Boehringer Ingelheim International GmbH - Business segments Exhibits114: Boehringer Ingelheim International GmbH - Key news Exhibits115: Boehringer Ingelheim International GmbH - Key offerings Exhibits116: Boehringer Ingelheim International GmbH - Segment focus Exhibits117: Cadila Pharmaceuticals Ltd. - Overview Exhibits118: Cadila Pharmaceuticals Ltd. - Product / Service Exhibits119: Cadila Pharmaceuticals Ltd. - Key offerings Exhibits120: Cipla Ltd. - Overview Exhibits121: Cipla Ltd. - Business segments Exhibits122: Cipla Ltd. - Key news Exhibits123: Cipla Ltd. - Key offerings Exhibits124: Cipla Ltd. - Segment focus Exhibits125: Exela Pharma Sciences LLC - Overview Exhibits126: Exela Pharma Sciences LLC - Product / Service Exhibits127: Exela Pharma Sciences LLC - Key offerings Exhibits128: GlaxoSmithKline Plc - Overview Exhibits129: GlaxoSmithKline Plc - Business segments Exhibits130: GlaxoSmithKline Plc - Key offerings Exhibits131: GlaxoSmithKline Plc - Segment focus Exhibits132: Lupin Ltd. - Overview Exhibits133: Lupin Ltd. - Product / Service Exhibits134: Lupin Ltd. - Key news Exhibits135: Lupin Ltd. - Key offerings Exhibits136: Merck and Co. Inc. - Overview Exhibits137: Merck and Co. Inc. - Business segments Exhibits138: Merck and Co. Inc. - Key news Exhibits139: Merck and Co. Inc. - Key offerings Exhibits140: Merck and Co. Inc. - Segment focus Exhibits141: Mundipharma International Ltd. - Overview Exhibits142: Mundipharma International Ltd. - Product / Service Exhibits143: Mundipharma International Ltd. - Key offerings Exhibits144: Novartis AG - Overview Exhibits145: Novartis AG - Business segments Exhibits146: Novartis AG - Key offerings Exhibits147: Novartis AG - Segment focus Exhibits148: Shionogi and Co. Ltd. - Overview Exhibits149: Shionogi and Co. Ltd. - Product / Service Exhibits150: Shionogi and Co. Ltd. - Key offerings Exhibits151: Sumitomo Pharma Co. Ltd. - Overview Exhibits152: Sumitomo Pharma Co. Ltd. - Business segments Exhibits153: Sumitomo Pharma Co. Ltd. - Key offerings Exhibits154: Sumitomo Pharma Co. Ltd. - Segment focus Exhibits155: Teva Pharmaceutical Industries Ltd. - Overview Exhibits156: Teva Pharmaceutical Industries Ltd. - Business segments Exhibits157: Teva Pharmaceutical Industries Ltd. - Key news Exhibits158: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibits159: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibits160: Theravance Biopharma Inc. - Overview Exhibits161: Theravance Biopharma Inc. - Product / Service Exhibits162: Theravance Biopharma Inc. - Key offerings Exhibits163: Viatris Inc. - Overview Exhibits164: Viatris Inc. - Business segments Exhibits165: Viatris Inc. - Key offerings Exhibits166: Viatris Inc. - Segment focus Exhibits167: Inclusions checklist Exhibits168: Exclusions checklist Exhibits169: Currency conversion rates for US$ Exhibits170: Research methodology Exhibits171: Validation techniques employed for market sizing Exhibits172: Information sources Exhibits173: List of abbreviations |
| ※참고 정보 만성 폐색성 폐질환(COPD)은 주요한 호흡기 질환으로, 주로 흡연이나 환경적 요인에 의해 발생하며, 만성 기관지염과 폐기종이 포함됩니다. 이 질환은 기도의 만성 염증, 기도 내구의 감소, 폐기능의 저하 등을 초래하여 호흡 곤란, 기침, 가래, 그리고 피로 등의 증상을 동반합니다. 치료는 증상을 완화하고 질병 진행을 늦추며, 환자의 삶의 질을 향상시키는 데 목적이 있습니다. COPD 치료제는 크게 흡입제와 경구약물로 나눌 수 있습니다. 흡입제는 환자가 직접 흡입하여 약물이 폐로 직접 전달되도록 하며, 이는 효과적인 약물 전달을 가능하게 합니다. 주요 종류로는 β2-아드레날린 작용제, 흡입 스테로이드, 그리고 항콜린제가 있습니다. β2-아드레날린 작용제는 기관지를 확장시켜 호흡을 용이하게 하며, 주로 단기 작용제와 장기 작용제로 나누어 사용됩니다. 단기 작용제는 급성 호흡 곤란 시 사용되고, 장기 작용제는 지속적인 증상 완화에 도움을 줍니다. 흡입 스테로이드는 염증을 억제하여 증상을 관리하는 데 중요하며, 병의 악화를 예방하는 데 기여합니다. 항콜린제는 기관지의 수축을 억제하여 기도를 확장시키는 역할을 합니다. 경구약물로는 경구 스테로이드와 테오필린이 있습니다. 경구 스테로이드는 염증을 억제하고, 심한 COPD 환자의 급성 악화를 예방하는 데 사용됩니다. 테오필린은 기관지를 확장시키고 호흡을 개선하는 데 도움이 되지만, 부작용의 위험이 있어 사용 시 주의가 필요합니다. COPD 치료에는 약물 외에도 비약물적 치료가 중요합니다. 흡연 중단은 모든 COPD 환자에게 가장 중요한 조치로 권장되며, 금연 프로그램이나 상담 서비스가 동반될 수 있습니다. 또한, 운동 요법, 호흡 치료, 영양 관리도 환자의 전반적인 상태를 개선하는 데 기여합니다. 또한, COPD 기술적 측면에서는 디지털 헬스케어의 발전이 주목받고 있습니다. 환자의 호흡 상태를 모니터링하고, 약물 사용을 추적하며, 맞춤형 치료를 제공하는 스마트 기기나 애플리케이션이 개발되고 있습니다. 이러한 기술은 환자의 치료 참여를 유도하고, 의사와의 상호작용을 개선하여 더욱 효과적인 치료를 가능하게 합니다. COPD는 만성질환으로 완치가 어려운 만큼, 조기 진단과 지속적인 관리가 필수적입니다. 치료제의 발전과 비약물적 치료에 대한 인식이 높아지면서, 많은 환자들이 보다 나은 삶을 누릴 수 있도록 돕고 있습니다. 이러한 다양한 접근 방법은 환자의 삶의 질을 높이고, COPD로 인한 사회적 부담을 줄이는 데 기여하고 있습니다. |
| ※본 조사보고서 [세계의 만성 폐색성 폐질환 치료제 시장 (2023년~2027년)] (코드 : IRTNTR70733-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 만성 폐색성 폐질환 치료제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

